As global competition in the weight-loss drug market intensifies, Novo Nordisk has announced it will fully promote the launch of its oral weight-loss drug, Wegovy tablets, in markets outside the United States. Emil Kongshoj Larsen, Executive Vice President of International Business at the company, stated that this represents a significant opportunity for the company to expand into overseas markets. Currently, both Novo Nordisk and Eli Lilly rely on the U.S. market for over half of their sales. However, as the weight-loss drug market landscape is reshaped, both companies are accelerating their layout (Note: translated as "strategic expansion") in potential markets such as the UK, Germany, and Denmark. Larsen revealed that the company will consider market potential, patient demand, physician expertise, and telemedicine collaboration resources as key criteria for its strategic layout (Note: translated as "expansion"), with telemedicine seen as a crucial avenue for expanding patient reach. Although Novo Nordisk expects its profits and sales to decline by 4%-12% in 2026 due to price reductions in the U.S. and competition from generic drugs in emerging markets, Wegovy tablets have made breakthrough progress in the U.S. market—accumulating over 2 million prescriptions since their launch in January 2026, with first-quarter sales reaching DKK 2.256 billion. Analysts point out that the product outperforms Eli Lilly's competing product, Foundayo, in terms of weight-loss efficacy and offers cardiovascular benefits. However, the growth curve in international markets may be more gradual than in the U.S. due to differences in pricing strategies.